Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

452 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
11C-Acetate PET imaging for renal cell carcinoma.
Oyama N, Okazawa H, Kusukawa N, Kaneda T, Miwa Y, Akino H, Fujibayashi Y, Yonekura Y, Welch MJ, Yokoyama O. Oyama N, et al. Eur J Nucl Med Mol Imaging. 2009 Mar;36(3):422-7. doi: 10.1007/s00259-008-0981-0. Epub 2008 Nov 19. Eur J Nucl Med Mol Imaging. 2009. PMID: 19018529
11C-acetate PET imaging of prostate cancer.
Oyama N, Akino H, Kanamaru H, Suzuki Y, Muramoto S, Yonekura Y, Sadato N, Yamamoto K, Okada K. Oyama N, et al. J Nucl Med. 2002 Feb;43(2):181-6. J Nucl Med. 2002. PMID: 11850482 Free article. Clinical Trial.
[Pet imaging in prostate cancer].
Oyama N, Kaneda T, Nakai M, Shioyama R, Matsuta Y, Tanase K, Aoki Y, Miwa Y, Akino H, Yokoyama O, Okazawa H, Fujibayashi Y, Yonekura Y. Oyama N, et al. Hinyokika Kiyo. 2006 Jun;52(6):503-5. Hinyokika Kiyo. 2006. PMID: 16848365 Japanese. No abstract available.
[PET, PET-CT].
Oyama N, Yokoyama O. Oyama N, et al. Nihon Rinsho. 2011 Jun;69 Suppl 5:280-4. Nihon Rinsho. 2011. PMID: 22207986 Review. Japanese. No abstract available.
Carbon-11-acetate positron emission tomography (PET), versus fluorine- 18 fluorodeoxyglucose PET and CT for the diagnosis of recurrent prostate cancer after radical prostatectomy in cases of prostate specific antigen of more than 1 to 3ng/mL.
Oyama N, Ito H, Aoki Y, Miwa Y, Akino H, Kudo T, Okazawa H, Fujibayashi Y, Welch M, Yokoyama O. Oyama N, et al. Hell J Nucl Med. 2013 May-Aug;16(2):146-7. Hell J Nucl Med. 2013. PMID: 24032176 No abstract available.
452 results